LEBANON, N.H.--(EON: Enhanced Online News)--Adimab, LLC, the global leader in the discovery and optimization of fully human monoclonal and bispecific antibodies, today announced that it has entered into definitive agreements with nine new companies in 2016. In addition, Adimab announced the expansion of seven of its current partnerships and the achievement of over 40 technical and development milestones across multiple existing collaborations.
“At Adimab, we are committed to continually improving and expanding our technical offering to provide the best antibody discovery platform in the industry”
Over the past eight years, Adimab has entered into over 40 partnerships for the discovery of therapeutic IgGs and bispecific antibodies, generating in excess of 150 therapeutic programs using the Adimab platform. The most advanced program is currently in Phase 2 clinical trials. New alliances for 2016 include collaborations with Takeda Pharmaceuticals, Iconic Therapeutics, Tizona Therapeutics, Scholar Rock, and iTeos Therapeutics, among others. In addition, Adimab expanded its partnerships with Innovent Biosciences and Jounce Therapeutics, and several others.
“We are focused on being a premier technology company, not a product company,” commented Guy Van Meter, Vice President of Business Development at Adimab. “Our success is entirely dependent upon the success of our partners and, therefore, every program is very important to us. Speed is a critical aspect for many of our partners, but identifying a therapeutic lead that provides a competitive advantage is even more important.”
“At Adimab, we are committed to continually improving and expanding our technical offering to provide the best antibody discovery platform in the industry,” added Tillman Gerngross, Chief Executive Officer and Co-Founder of Adimab. “We want our partners to have solutions for all of their therapeutic approaches so that Adimab is the partner of choice in turning their biological insights into transformative drugs.”
Adimab also announced that it achieved over 40 technical and development milestones in 2016 with Merck, Kyowa Hakko Kirin, Kite Pharma, Surface Oncology, GSK, and several others. Adimab partners exercised a total of 13 commercial licenses in 2016, in addition to Mersana and Innovent filing INDs and Arsanis advancing its lead program into Phase 2 clinical trials.
“Adimab was able to rapidly identify and screen a large number of antibodies that interact with HER2 in unique ways; this allowed us to select a lead antibody with superior ADC properties. XMT1522, our lead program, is comprised of this antibody conjugated to our highly differentiated Dolaflexin ADC platform, and has shown superior efficacy and tolerability in a broad range of pre-clinical models,” said Anna Protopapas, Chief Executive Officer of Mersana Therapeutics. ”Phase 1 trials for XMT1522 are ongoing.”
“We have pursued numerous programs with Adimab and have experienced excellent success. Our anti-PD1 program has initiated clinical trials in 2016, a mere two years after completing our campaign with Adimab,” added Michael Wu, Chief Executive Officer at Innovent. “The speed of the Adimab technology has helped Innovent rapidly develop multiple products.”
Adimab has established antibody discovery collaborations with many leading pharmaceutical companies, such as Merck, Novo Nordisk, Biogen, GSK, Roche, Novartis, Eli Lilly, Genentech, Celgene, Gilead, Kyowa Hakko Kirin, Takeda and Sanofi. In addition, Adimab has partnered with several smaller publicly traded companies, such as Acceleron, Merrimack Pharmaceuticals, Kite, Five Prime, as well as leading venture-backed companies including Jounce, Mersana, Alector, Arsanis, Surface Oncology, Potenza, Tizona, Tusk and several academic institutions such as Memorial Sloan Kettering and MD Anderson. The Adimab antibody discovery and optimization platform has also been internalized by several larger pharma partners; Adi-inside partners include Merck, Novo Nordisk, Biogen and GSK.
Adimab’s integrated antibody discovery and optimization platform provides unprecedented speed from antigen to purified, full-length human IgGs. Adimab offers fundamental advantages by delivering diverse panels of therapeutically relevant antibodies that meet the most aggressive standards for affinity, epitope coverage, species cross-reactivity and developability. Adimab enables its partners to rapidly expand their biologics pipelines through a broad spectrum of technology access arrangements. For more information, visit http://www.adimab.com.